ESO Ovarian Cancer Observatory: Innovation and care in the next 12 months
Not eligible for ESCO credits
05.11.2019
Athens, Greece
OBSERVATORY
Description
Chair: C. Sessa, CH
AIMS AND OBJECTIVES
ESO Observatories are high level sessions organised during major international congresses with the aim of providing the audience with updated and unbiased information on a given topic. An ESO Observatory lasts about one hour and concentrates on a forecast given by panel of experts of what it is expected to happen in their own field in the coming 12 months. The Panel includes distinguished clinicians and/or scientists and a patient or patient advocate.
For each topic, the forecast by each Panel Member is given in the form of take-home concise message with 8-minute slide presentation followed by 2 minutes of discussion with the Panel.
The Observatory will be held during |
Panelists
PANELISTS
C. Gourley, The University of Edinburgh, Western General Hospital, Edinburgh, UK
C. Hierro, ASACO - Asociación de Afectados por Cáncer de Ovario, Madrid, ES
J. Ledermann, University College London Cancer Institute, London, UK
J. Matias-Guiu Guia, Institut de Recerca Biomedica Lleida, Lleida, ES
D. Querleu, Institut Bergonié Cancer Center, Bordeaux, FR
E. Saloustros, University Hospital of Larissa, Larissa, GR
C. Sessa, Oncology Institute of Southern Switzerland, Bellinzona, CH
General information
ESO SECRETARIAT
Roberta Ventura, Gynaecological Cancers Programme
European School of Oncology
Piazza Indipendenza 2
6500 Bellinzona
Switzerland
Email: rventura@eso.net
Tel: +41 91 820 09 57
VENUE
The Observatory will be held during the ESGO 2019.
MEGARON
Athens International Conference Centre
Vass. Sofias & Kokkali
11521 Athens, Greece
www.maicc.gr
FURTHER INFORMATION
Attendance is granted to all participants registered to the ESGO 2019 Congress.
Programme
5 November
11:00-12:30 (Room: Alexandra Trianti) Chair: C. Sessa, CH |
||
11:00 | Introduction C. Sessa, CH |
|
11:05 | The pathologist’s perspective X. Matias-Guiu Guia, ES |
|
11:15 | The clinical scientist’s perspective C. Gourley, UK |
|
11:25 | The clinical genetist’s perspective E. Saloustros, GR |
|
11:35 | The gyneco-oncologist’s perspective D. Querleu, FR |
|
11:45 | The medical oncologist’s perspective J. Ledermann, UK |
|
11:55 | The patient’s perspective C. Hierro, ES |
|
12:05- 12:30 |
Discussion and take-home messages |